Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis

Bone

Volumn 79, Issue , 2015, Pages 65-70

  Shimizu, Tomohiro ^a   Takahata, Masahiko ^a   Kameda, Yusuke ^a   Endo, Tsutomu ^a   Hamano, Hiroki ^a   Hiratsuka, Shigeto ^a   Ota, Masahiro ^a   Iwasaki, Norimasa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antigen induced arthritis; DAP12; Osteoclast; Sialic acid; Siglec 15

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 17; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 15; UNCLASSIFIED DRUG; IMMUNOGLOBULIN; MEMBRANE PROTEIN; SIGLEC-15 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE LESION; BONE MARROW CELL; CARTILAGE DEGENERATION; CELL MATURATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TARGETING; FEMALE; FEMUR; KNEE ARTHRITIS; METAPHYSIS; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TIBIA; WILD TYPE; ANIMAL; BONE; C57BL MOUSE; EXPERIMENTAL ARTHRITIS; INFLAMMATION; JOINT; KNOCKOUT MOUSE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; OSTEOBLAST; OSTEOCLAST; PATHOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; FEMALE; IMMUNOGLOBULINS; INFLAMMATION; JOINTS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; REAL-TIME POLYMERASE CHAIN REACTION; X-RAY MICROTOMOGRAPHY;

EID: 84930630601     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.05.029     Document Type: Article

References (32)

1. Gough A.K., Lilley J., Eyre S., Holder R.L., Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.
2. Hansen M., Florescu A., Stoltenberg M., Podenphant J., Pedersen-Zbinden B., Horslev-Petersen K., et al. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scand J Rheumatol 1996, 25:367-376.
3. Alenfeld F.E., Diessel E., Brezger M., Sieper J., Felsenberg D., Braun J. Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int 2000, 11:400-407.
4. Cohen S.B., Dore R.K., Lane N.E., Ory P.A., Peterfy C.G., Sharp J.T., et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309.
5. Deodhar A., Dore R.K., Mandel D., Schechtman J., Shergy W., Trapp R., et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010, 62:569-574.
6. Miller P.D., Wagman R.B., Peacock M., Lewiecki E.M., Bolognese M.A., Weinstein R.L., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2010, 96:394-402.
7. Kaifu T., Nakahara J., Inui M., Mishima K., Momiyama T., Kaji M., et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003, 111:323-332.
8. Humphrey M.B., Ogasawara K., Yao W., Spusta S.C., Daws M.R., Lane N.E., et al. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res 2004, 19:224-234.
9. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004, 428:758-763.
10. Mocsai A., Humphrey M.B., Van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004, 101:6158-6163.
11. Angata T., Hayakawa T., Yamanaka M., Varki A., Nakamura M. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J 2006, 20:1964-1973.
12. Angata T., Tabuchi Y., Nakamura K., Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 2007, 17:838-846.
13. Kameda Y., Takahata M., Komatsu M., Mikuni S., Hatakeyama S., Shimizu T., et al. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling adaptor DAP12. J Bone Miner Res 2013, 28:2463-2475.
14. Crotti T.N., Dharmapatni A.A., Alias E., Zannettino A.C., Smith M.D., Haynes D.R. The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther 2012, 14:R245.
15. Alias E., Dharmapatni A.S., Holding A.C., Atkins G.J., Findlay D.M., Howie D.W., et al. Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomater 2012, 8:3104-3112.
16. van Lent P.L., Grevers L., Lubberts E., de Vries T.J., Nabbe K.C., Verbeek S., et al. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum 2006, 54:3868-3877.
17. Ochi S., Shinohara M., Sato K., Gober H.J., Koga T., Kodama T., et al. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A 2007, 104:11394-11399.
18. Joyce-Shaikh B., Bigler M.E., Chao C.C., Murphy E.E., Blumenschein W.M., Adamopoulos I.E., et al. Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med 2010, 207:579-589.
19. Wong P.K., Quinn J.M., Sims N.A., van Nieuwenhuijze A., Campbell I.K., Wicks I.P. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006, 54:158-168.
20. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
21. Williams A.S., Mizuno M., Richards P.J., Holt D.S., Morgan B.P. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 2004, 50:3035-3044.
22. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
23. Hiruma Y., Hirai T., Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem Biophys Res Commun 2011, 409:424-429.
24. Takahata M., Iwasaki N., Nakagawa H., Abe Y., Watanabe T., Ito M., et al. Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone 2007, 41:77-86.
25. Kameda Y., Takahata M., Mikuni S., Shimizu T., Hamano H., Angata T., et al. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Bone 2015, 71:217-226.
26. Stuible M., Moraitis A., Fortin A., Saragosa S., Kalbakji A., Filion M., et al. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J Biol Chem 2014, 289:6498-6512.
27. Wu Y., Torchia J., Yao W., Lane N.E., Lanier L.L., Nakamura M.C., et al. Bone microenvironment specific roles of ITAM adapter signaling during bone remodeling induced by acute estrogen-deficiency. PLoS One 2007, 2:e586.
28. Turnbull I.R., Colonna M. Activating and inhibitory functions of DAP12. Nat Rev Immunol 2007, 7:155-161.
29. Hamerman J.A., Lanier L.L. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006, re1.
30. Herman S., Muller R.B., Kronke G., Zwerina J., Redlich K., Hueber A.J., et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 2008, 58:3041-3050.
31. Ferraccioli G., Bracci-Laudiero L., Alivernini S., Gremese E., Tolusso B., De Benedetti F. Interleukin-1beta and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med 2010, 16:552-557.
32. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Nomura S., et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998, 95:8222-8226.